Editorial
Copyright ©The Author(s) 2015.
World J Nephrol. Jul 6, 2015; 4(3): 324-329
Published online Jul 6, 2015. doi: 10.5527/wjn.v4.i3.324
Table 2 Studies of uric-acid-lowering therapy in renal allograft recipients
Ref.Study populationAverage follow-upIntervention/outcome(s)Main study findings
Perez-Ruiz et al[34]279 renal allograft recipients with hyperuricemia38.6 ± 18.4 moAllopurinol, benziodarone/ serum UA levelsBoth drugs effective in lowering serum UA; benziodarone safer in patients on azathioprine
Numakura et al[11]121 renal allograft recipients with and without hyperuricemiaUp to 10 yr, mean not reportedAllopurinol/eGFR, graft survivalHyperuricemia associated with reduced eGFR, but graft survival similar in normo and hyperuricemic patients
Osadchuck et al[35]108 renal allograft recipients (54 patients treated vs 54 controls)2 yrAllopurinol/Serum UA levels, eGFR, graft survivalReduced serum UA, preservation of eGFR in allopurinol treated patients; no differences in graft survival and blood pressure
Sofue et al[36]93 renal allograft recipients (42 normouricemic, 51 hyperuricemic, 26 treated, 25 not treated)1 yrFebuxostat/serum UA levels, eGFRSerum UA lower and eGFR stable in patients treated with febuxostat
Tojimbara et al[38]23 renal allograft recipients with hyperuricemia12 ± 2 moFebuxostat/serum UA, eGFRSerum UA lower after treatment with febuxostat; eGFR stable